Fig. 4: Confirmation that the methylome-based predictor and clinical-methylomic nomogram were developed to discriminate BM outcomes across the spectrum of LUAD disease.
From: Prediction of brain metastasis development with DNA methylation signatures
a, Kaplan–Meier plots with log-rank tests showing that BM predictor output tertiles distinguish patients with high, intermediate and low risk for BM development across cancer stages (top) and both EGFR mutation statuses (bottom). b, Kaplan–Meier plots with log-rank tests showing that BM nomogram scores stratified according to the median distinguish high-risk and low-risk patients across both EGFR mutation statuses.
